Point-of-Care Diagnosis and Prognostication of Cryptococcal Meningitis With the Cryptococcal Antigen Lateral Flow Assay on Cerebrospinal Fluid

Taseera Kabanda,1,a Mark J. Siedner,2,a Jeffrey D. Klausner,3 Conrad Muzoora,1 and David R. Boulware4

1Department of Medicine, Faculty of Medicine, Mbarara University of Science and Technology, Uganda; 2Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston; 3Department of Medicine, Center for World Health and Division of Infectious Diseases, University of California, Los Angeles; and 4Division of Infectious Diseases and International Medicine, Department of Medicine, University of Minnesota, Minneapolis

The cryptococcal antigen (CRAG) lateral flow assay (LFA) had 100% sensitivity and specificity on cerebrospinal fluid samples. Pretreatment LFA titers correlated with quantitative cultures ($R^2 = 0.7$) and predicted 2- and 10-week mortality. The CRAG LFA is an accurate diagnostic assay for CSF and should be considered for point-of-care diagnosis of cryptococcal meningitis.

Keywords. HIV; cryptococcal meningitis; diagnosis; point-of-care; sub-Saharan Africa.

A lateral flow immunochromatographic assay (LFA; Immy Inc, Norman, Oklahoma) for detection of cryptococcal antigen (CRAG) has been recently developed. The test can be performed without electricity in ≤10 minutes, is stable at room temperature, and costs $2 per strip in low-income countries. Those features make it an attractive option for diagnosis of cryptococcal disease in resource-limited settings.

Reports of the CRAG LFA diagnostic accuracy are limited to studies with few cerebrospinal fluid (CSF) samples, and those performed in clinical laboratories [1, 2]. Use of the CRAG LFA as a clinical point-of-care test in CSF specimens would enable rapid meningitis diagnosis, and differentiation between uncomplicated infection and meningitis among those patients whose samples are positive by serum CRAG testing [3]. Furthermore, the LFA’s prognostic significance or ability to monitor treatment response is unknown. We estimated the accuracy and prognostic value of the CRAG LFA as a point-of-care test on CSF specimens by comparing LFA to standard diagnostic tests and correlating LFA CRAG titers with mortality among human immunodeficiency virus (HIV)–infected persons with suspected meningitis at a regional hospital in southwestern Uganda.

MATERIALS AND METHODS

Participants and Ethics Statement
Samples were collected as part of 2 prospective cohorts: (1) a randomized trial from 2011–2012 including 112 patients with suspected meningitis (clinicaltrials.gov: NCT01075152), in which patients with confirmed cryptococcal meningitis received induction therapy with 2 weeks of amphotericin B and flucytosine, and were randomized to early or deferred antiretroviral therapy (ART) initiation [4]; and (2) a prospective cohort study from 2008–2009 of 30 patients with confirmed cryptococcal meningitis (by India ink testing), who received short-course amphotericin B (5 days) and flucytosine for 2 weeks [5]. All participants were recruited after written informed consent at Mbarara Regional Referral Hospital. Study procedures were approved by all relevant institutional review boards.

Laboratory Procedures
We collected CSF for CRAG latex agglutination assay (Meridian Bioscience, Cincinnati, Ohio) and CRAG LFA (IMMY, Inc, Norman, Oklahoma); both were performed according to the manufacturer’s instructions, as well as India ink staining and quantitative CSF culture with quantitative dilutions, as described previously [6, 7]. In the cohort study (n = 30), we tested additional CSF samples on days 3, 7, and 14 for LFA and fungal culture, which were performed on cryopreserved specimens. Semiquantitative LFA titers were performed with 2-fold CSF dilutions from 1:10 up to the greatest dilution with a positive reaction.

Statistical Analyses
We first assessed accuracy of the CSF CRAG LFA compared to a composite reference standard, defined as ≥2 positive tests, to avoid incorporation bias [8]. Repeated lumbar punctures...
within 14 days could further inform the reference standard for initially discordant specimens. We restricted this analysis to specimens from the randomized clinical trial \((n = 112)\) because the cohort study had positive India ink as an inclusion criterion.

Next, we used repeated measurements from the cohort study \((n = 30)\) to correlate CSF CRAG titers and quantitative fungal cultures at baseline, and at days 3, 7, and 14 of treatment. Specifically, we compared fungal culture log_{10} colony-forming units (CFU)/mL and log_{2} LFA titers by calculating \(R^2\) and fitting linear regression models. We also compared the change in log_{10} CFU/mL per day (also known as early fungicidal activity) to change in log_{2} LFA titer per day \([9]\).

Finally, we used data from both studies to measure the association between baseline CSF CRAG LFA titer and quantitative fungal culture and both 2- and 10-week mortality, adjusted for Glasgow Coma Scale (GCS; dichotomized by <15 or 15). All statistical analyses were performed with Stata software, version 11.2 (StataCorp, College Station, Texas).

RESULTS

Forty-seven of 112 subjects \((42\%)\) with suspected meningitis had cryptococcal meningitis by the reference standard: 41 aseptic meningitis, 12 suspected tuberculous meningitis, 6 normal CSF parameters, 3 Streptococcus pneumoniae meningitis, 2 suspected bacterial meningitis, and 1 cerebral malaria. Subjects with cryptococcal meningitis had a median GCS of 15 \((\text{range}, 8–15)\) and median CD4 count of 27 cells/µL \((\text{interquartile range}, 12–66)\). The diagnostic performance of each assay is presented in Table 1. Both the sensitivity and specificity of LFA CRAG were 100%, and there was high concordance between diagnostic modalities \((107/112)\).

We found a high correlation between log_{10} CFU and log_{2} LFA titers on day 1 \((n = 142, R^2 = 0.70, P < .001)\). However, in the subgroup with repeated titers on treatment \((n = 30)\), the correlation between log_{10} CFU and log_{2} LFA CRAG titers decreased from day 3 \((R^2 = 0.69, P < .001)\) to day 7 \((R^2 = 0.30, P = .005)\) to day 14 \((R^2 = 0.20, P = .03)\) \((\text{Supplementary Figure 1})\). On day 14, 9 of 11 culture-negative samples had positive LFA titers. There was no correlation between change in log_{10} CFU \((\text{median}, –0.31)\) and change in log_{2} LFA titers during time on treatment \((\text{median}, –0.06)\) \((R^2 = 0.10, P = .11; \text{Supplementary Figure 2})\).

Among 70 participants followed prospectively, the crude mortality rate was 21% \((15/70)\) at 2 weeks and 32% \((22/69)\) at 10 weeks. Mortality rates were significantly higher for those with an LFA titer \(\geq 1:1280\) at both 2 weeks \((12/35\) vs \(2/35\)) and 10 weeks \((14/34\) vs \(7/35, P < .05\) for both comparisons \(\text{Figure 1})\). In multivariable models adjusted for GCS score, both pretreatment CSF quantitative culture CFU/mL and LFA titer were associated with mortality. Each doubling of the LFA titer was associated with an estimated 1.8-fold increased odds of 2-week mortality and a 30% increased odds of 10-week mortality.

DISCUSSION

We report that the CRAG LFA point-of-care test in CSF specimens is a highly sensitive and specific test for cryptococcal meningitis. Additionally, CSF CRAG LFA titers at time of diagnosis correlate with fungal burden and are associated with mortality at 2 and 10 weeks. Because the CRAG LFA is a rapid, low-cost assay, and can be performed without electricity by healthcare workers with minimal training, the CRAG LFA fills the need for a point-of-care test for cryptococcal meningitis diagnosis in resource-limited settings. This need is increasingly relevant as Cryptococcus is the most common cause of adult meningitis in Africa \([10]\), causing 20%–25% of AIDS-related mortality in Africa \([11]\). World Health Organization guidelines recommend systematic implementation of pre-ART CRAG screening from serum or whole blood specimens for HIV-infected persons with CD4 counts \(\leq 100\) cells/µL \([3]\). The CRAG LFA on CSF is a feasible option for confirming or excluding meningitis in those with positive blood tests.

Our findings add to the evidence that LFA is a highly accurate assay for the diagnosis of cryptococcal meningitis. A study that included 9 patients with positive CSF fungal cultures found that all were positive by CSF LFA \([1]\). A second study

Table 1. Diagnostic Performance of Tests for Cryptococcal Meningitis Using Cerebrospinal Fluid Specimens Collected in Southwestern Uganda \((n = 112)\)

<table>
<thead>
<tr>
<th>Test</th>
<th>Sensitivity</th>
<th>95% CI</th>
<th>Specificity</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>CRAG LFA</td>
<td>100% (47/47)</td>
<td>92.5%–100%</td>
<td>100% (65/65)</td>
<td>94.5%–100%</td>
</tr>
<tr>
<td>CRAG latex</td>
<td>100% (47/47)</td>
<td>92.5%–100%</td>
<td>98.5% (64/65)</td>
<td>91.7%–100%</td>
</tr>
<tr>
<td>CSF culture</td>
<td>95.7% (45/47)</td>
<td>85.5%–99.5%</td>
<td>100% (65/65)</td>
<td>94.5%–100%</td>
</tr>
<tr>
<td>India ink</td>
<td>93.6% (44/47)</td>
<td>82.5%–98.7%</td>
<td>100% (65/65)</td>
<td>94.5%–100%</td>
</tr>
</tbody>
</table>

Abbreviations: CI, confidence interval; CRAG, cryptococcal antigen; CSF, cerebrospinal fluid; LFA, lateral flow assay.

* Of 2 culture-negative patients, 1 was positive by the 3 other tests; the second was CRAG positive by LFA and latex, but was diagnosed with culture positive cryptococcal meningitis 2 weeks later.
Figure 1. Two- and 10-week mortality by pretreatment cryptococcal antigen lateral flow assay titer. Error bars signify 1 standard deviation. P values denote results of χ² testing between groups. Multivariable analyses are adjusted for pretreatment Glasgow Coma Scale score at diagnosis. Odds ratios are per each increase in pretreatment log₁₀ colony-forming units per milliliter of cerebrospinal fluid culture at diagnosis, and per each 2-fold dilution >1:10 in pretreatment cryptococcal antigen lateral flow assay titer at diagnosis. Abbreviations: CFU, colony-forming unit; CI, confidence interval; CSF, cerebrospinal fluid; LFA, lateral flow assay.

<table>
<thead>
<tr>
<th>Variable</th>
<th>2-Week Mortality</th>
<th>10-Week Mortality</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Odds Ratio</td>
<td>95% CI</td>
</tr>
<tr>
<td>log₁₀ CFU/mL CSF</td>
<td>3.8 (1.6–6.9)</td>
<td>.003</td>
</tr>
<tr>
<td>log₁₀ LFA titer</td>
<td>1.8 (1.2–2.7)</td>
<td>.003</td>
</tr>
<tr>
<td></td>
<td>1.9 (1.1–3.6)</td>
<td>.023</td>
</tr>
<tr>
<td></td>
<td>1.3 (1.0–1.8)</td>
<td>.047</td>
</tr>
</tbody>
</table>

Two- and 10-week mortality by pretreatment cryptococcal antigen lateral flow assay titer. Error bars signify 1 standard deviation. P values denote results of χ² testing between groups. Multivariable analyses are adjusted for pretreatment Glasgow Coma Scale score at diagnosis. Odds ratios are per each increase in pretreatment log₁₀ colony-forming units per milliliter of cerebrospinal fluid culture at diagnosis, and per each 2-fold dilution >1:10 in pretreatment cryptococcal antigen lateral flow assay titer at diagnosis. Abbreviations: CFU, colony-forming unit; CI, confidence interval; CSF, cerebrospinal fluid; LFA, lateral flow assay.

compared CSF LFA to enzyme immunoassay CRAG testing and found 100% sensitivity (15/15) and 99.7% specificity (395/396) [2]. Notably, we found some evidence that the LFA is possibly more sensitive than fungal culture at early stages of disease. Two subjects had low LFA titers (1:10) with negative fungal culture; both were CRAG-latex positive and 1 was India ink positive. Both subjects underwent repeat testing within 14 days and were found to have culture-confirmed cryptococcal meningitis.

We also found evidence for a prognostic value of pretreatment CSF LFA titers. Both quantitative culture and higher latex-CRAG titers were predictive of adverse outcomes [12–15]. We found a higher correlation between pretreatment quantitative fungal cultures and pretreatment LFA titers (R² = 0.7, P < .001) than a prior study correlating latex agglutination CRAG titer and culture CFU (R² = 0.5) [16]. Moreover, we found increasing 2- and 10-week mortality with each 2-fold titer increase in CSF LFA. This finding is in keeping with a prior study that found a relationship between latex agglutination CRAG titers and mortality risk [16]. Because quantitative cultures are unavailable in much of the developing world, the LFA titers, which can be simply performed with serial dilutions, might serve an important additional prognostic role to advise clinicians on mortality risk. Although the cost of additional titers ($2 per titer) might present a challenge, a titer threshold of >1:1000 could be considered prognostic to minimize need for additional dilutions, based on our finding that a titer ≥1:1280 vs ≤640 was associated with 6-fold greater mortality at 2 weeks (Figure 1).

The LFA, however, should not be used to monitor treatment response. Because clearance of the cryptococcal capsule polysaccharide (ie, CRAG) by macrophages is an independent and slower process than killing of the yeast by antifungal therapy [16, 17], LFA titers remain elevated during effective treatment [16, 18, 19]. Thus, CRAG titers are not a suitable substitute for quantitative culture for determination of treatment response.

Limitations included the moderate sample size at a single center and use of archived specimens in the prospective cohort subgroup. However, given the confidence intervals around our accuracy estimates, a larger sample size would likely not have altered our conclusions greatly. Testing of samples in real time outside of a research setting will also be important to confirm the feasibility of LFA as a point-of-care test.

In summary, the LFA in CSF is an accurate and prognostic point-of-care test for cryptococcal meningitis. As cryptococcal meningitis remains the most common cause of adult meningitis in sub-Saharan Africa, and standard diagnostic techniques pose challenges in terms of cost and human resource needs, adoption of LFA as a point-of-care test on CSF should be urgently considered.

Supplementary Data

Supplementary materials are available at Clinical Infectious Diseases online (http://cid.oxfordjournals.org). Supplementary materials consist of data provided by the author that are published to benefit the reader. The posted materials are not copied. The contents of all supplementary data are the sole responsibility of the authors. Questions or messages regarding errors should be addressed to the author.

Notes

Acknowledgments. We thank Nicky Longley and Tom Harrison for collaboration and support with the short-course amphotericin B cohort. We thank Neal Wetherall, Mandana Godard, and the National Institutes of Health, National Institute of Allergy and Infectious Diseases (NIAID), Division of AIDS team for support of the laboratory’s external quality assurance testing in 2010–2012.

Financial support. Research and salary support was provided by the NIAID (U01AI089244, K23AI073192, T32AI007433), the National Institute of Mental Health (K23099916), and the Medical Research Council (UK).

Potential conflicts of interest. All authors: No reported conflicts.

All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

References


